Dendrite's Shareholders Approve Acquisition by Cegedim

  
    
  
  
    
      Dendrite International, Inc. (NASDAQ: DRTE) announced today that, at a 
      special meeting held in Bedminster, NJ, Dendrite’s 
      shareholders approved its acquisition by French company, Cegedim SA 
      ("Cegedim"). Subject to satisfaction of certain regulatory approvals and 
      other customary closing conditions, Dendrite expects the transaction to 
      be completed on or about May 9, 2007.
    
    
      On March 2, 2007, Dendrite announced that it had entered into an 
      agreement to be acquired by Cegedim in a merger transaction. Cegedim has 
      agreed to pay $16.00 in cash for each outstanding common share of 
      Dendrite upon the closing of the merger.
    
    
      About Dendrite
    
    
      Founded in 1986, Dendrite International enables sales, marketing, 
      clinical and compliance solutions for the global pharmaceutical 
      industry. The Company's clients are located in more than 50 countries 
      and include the world's top 20 pharmaceutical companies. For more 
      information, please visit http://www.dendrite.com.
    
    
      Note: Dendrite is a registered trademark of Dendrite International, Inc.
    
    
      Forward Looking Statements
    
    
      This press release contains certain statements that are “forward-looking 
      statements” within the meaning of Section 27A 
      of the Securities Act of 1933 and Section 21E of the Securities Exchange 
      Act of 1934, as amended. Such statements are qualified by the inherent 
      risks and uncertainties surrounding future expectations generally, and 
      also may materially differ from actual future experience involving any 
      one or more of such statements. Such risks and uncertainties include: 
      Dendrite’s inability to satisfy the conditions 
      to closing the merger and other risk factors as set forth from time to 
      time in Dendrite’s filings with the SEC. The 
      inclusion of a forward-looking statement herein should not be regarded 
      as a representation by Dendrite that Dendrite’s 
      objectives will be achieved. Dendrite undertakes no obligation to 
      publicly update forward-looking statements, whether as a result of new 
      information, future events or otherwise.